Compare Hudbay Minerals Inc. Ordinary Shares (Canada) (HBM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hudbay Minerals Inc. Ordinary Shares (Canada) vs Tango Therapeutics Inc. — how do they compare? Hudbay Minerals Inc. Ordinary Shares (Canada) trades at $23.99 (market cap $11.37B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Hudbay Minerals Inc. Ordinary Shares (Canada) is far larger — about 3× Tango Therapeutics Inc.'s market cap, and Hudbay Minerals Inc. Ordinary Shares (Canada) pays a 0.11% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hudbay Minerals Inc. Ordinary Shares (Canada) for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| HBM | TNGX | |
|---|---|---|
Market Cap | $11.37B | $3.75B |
Volume | 3,520,423 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $31.87 | $32.90 |
52-Week Low | $14.58 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.43B | $2.77B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HudBay Minerals (HBM) trades at $25.68, down 0.31% with bearish technical signals despite solid fundamentals. The company reported strong 2025 results with $2.21B revenue and $568.5M net income, while analyst consensus remains positive with 60% buy ratings. Recent news highlights HBM4 equipment delays and copper/gold reserve expansions at Snow Lake operations.
HBM presents a value opportunity with reasonable valuation (P/E 15.77) and strong profitability (ROE 18.43%), though technical weakness and HBM market dynamics pose near-term risks. The stock's outlook depends on execution of copper growth strategy and resolution of memory sector supply chain concerns.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hudbay Minerals Inc. Ordinary Shares (Canada)
Hudbay Minerals is a mining company producing copper, gold, zinc, and other metals. Its operations are located in the Americas.
Read more on HBM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
